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Background: The JAK2 V617F mutation is associated with three myeloproliferative neoplasms (MPNs): polycy-
themia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). It generates an unregu-
lated clonal hematopoietic progenitor and leads to abnormal increased proliferation of one or more myeloid
lineages. Subjects bearing this mutation may present more frequently with complications such as thrombosis and
bleeding, and no specific treatment has yet been developed for BCR-ABL-negative JAK2 V617F-negative MPNs.
Aims: To determine the prevalence of JAK2 V617F in MPNs in Pernambuco, Brazil, and to compare it with
previous studies. Material and Methods: 144 blood samples were collected at the Hospital of Hematology of the
HEMOPE Foundation and were genotyped by polymerase chain reaction–restriction fragment length poly-
morphism with BsaXI enzymatic digestion. Results and Discussion: 88% (46/52) of the patients with PV, 47% (39/
81) with ET, and 77% (8/11) with PMF were positive for JAK2 V617F, while more than 35% of the individuals
were JAK2 V617F-negative, confirming a high prevalence of this abnormality in MPNs, more frequently with a
low mutated allele burden, similar to what has been reported in other Western countries, despite differences
among methods used to detect this mutation. Screening for JAK2 V617F may allow specific management of these
diseases with JAK2 inhibitors in the future and highlights the need for further studies on the pathogenesis of
BCR-ABL-negative JAK2 V617F-negative MPNs.
Introduction
Myeloproliferative neoplasms (MPNs) are clonalhematopoietic diseases in which one or more myeloid
lineages present with abnormally increased levels of cell
proliferation. They are characterized by a multipotent pro-
genitor cell that proliferates independently from physiologi-
cal levels of growth factors such as erythropoietin (EPO) and
thrombopoetin, leading to accelerated hematopoiesis and
bone marrow hypercellularity (Baxter et al., 2005). Differently
from chronic myeloid leukemia, BCR-ABL-negative MPNs
have variable association with bleeding, thrombotic events,
marrow fibrosis, and less frequently blastic transformation
(Lussana et al., 2009).
JAK2 is a member of the janus kinases ( JAKs) family,
a group of cytoplasmic tyrosine kinases that transduce
cytokine-mediated signals via the JAK-signal transducers and
activators of transcription (STAT) pathway. Four JAKs have
been described: JAK1, JAK2, JAK3, and TYK2 (Ward et al.,
2000). When activation of a receptor by a cytokine occurs,
JAK2 becomes phosphorylated and causes further phos-
phorylation and dimerization of the STAT5 protein. STAT5
dimers enter the nucleus and act as transcription factors for
gene regulation. The JAK2 gene is localized in chromosomal
region 9p24 and was first cloned in 1989 in a cDNA library of a
murine cell lineage (Wilks, 1989).
The JAK2 V617F point mutation generates the substitution
of a guanidine for a thymidine in the encoding sequence
(1848G > T), resulting in the exchange of a valine residue for a
phenylalanine at position 617 of the mutated JAK2 protein.
This appears to relieve the inhibitory effect of the pseudoki-
nase domain ( JH2) on the kinase activity domain ( JH1),
leading to an unregulated proliferation in myeloid/erythroid
cells (Baxter et al., 2005; James et al., 2005; Vainchenker et al.,
2011). JAK2 constitutive activation causes hypersensitivity
to several cytokines known to stimulate hematopoietic
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precursors, such as EPO, thrombopoietin, interleukin 3,
granulocyte-macrophage colony-stimulating factor, and stem
cell factor (Levine and Wernig, 2006; Monte-Mór et al., 2007).
Other changes in mutated cells involve STAT5-mediated
signaling, extracellular signal regulated kinases, and phos-
phoinositol kinase/Akt pathways (Parganas et al., 1998;
Campbell and Green, 2006; Lippert et al., 2006).
This mutation is now recognized as an important
oncogenic event responsible for the development of BCR-
ABL-negative MPNs, such as polycythemia vera (PV) rubra,
essential thrombocythemia (ET), and primary myelofibrosis
(PMF). The discovery of the JAK2 V617F mutation was most
important to the diagnosis of PV, as it is present in more than
90% of individuals with this MPN. This allowed better char-
acterization of PV in contrast to other MPNs and validated the
clinical diagnostic criteria for this disease. (Tefferi et al., 2007).
JAK2 V617F has been found in more than 90% of PV cases,
but also in up to 60% of ET and PMF patients (Monte-Mór
et al., 2007; Haferlach et al., 2008; Scott et al., 2009). Since the
mutation is not universally present, other genetic events are
believed to be involved in the etiopathogenesis of both ET and
PMF, as well as JAK2 V617F-negative PV.
Several research groups have reported the somatic mutation
V617F in the gene encoding JAK2 in patients with BCR-ABL-
negative MPNs, and molecular studies in different regions of
the world, such as the United States, Europe, Middle East,
India, Korea, Japan, Argentina, and Southeastern Brazil, have
investigated its prevalence (Baxter et al., 2005; James et al., 2005;
Kravolics et al., 2005; Levine and Wernig, 2006; Monte-Mór
et al., 2007; Bang et al., 2009; Basquiera et al., 2009; Sazawal et al.,
2010; Ayad and Nafea, 2011; Mahfouz et al., 2011).
The aims of this study were to determine the prevalence of
JAK2 V617F in patients with BCR-ABL-negative MPNs at the
Hospital of Hematology at the HEMOPE Foundation, and to
compare our results with previous studies.
Materials and Methods
This study was performed after approval by the local ethics
committee of the HEMOPE Foundation. All samples were
collected on informed consent.
Patients were recruited at the Hospital of Hematology in
Recife, Pernambuco, Brazil, based on the clinical diagnosis of
the main three BCR-ABL-negative MPNs (PV, ET and PMF).
Between May 2009 and August 2010, 144 peripheral blood
samples were collected in vacuum collecting tubes containing
ethylenediaminetetraacetic acid as anticoagulant.
Peripheral blood granulocytes were separated by gradient
centrifugation with Ficoll-Paque (Sigma) to enhance test
sensitivity (Hermouet et al., 2007). DNA was extracted using
standard phenol-chlorophorm protocol (Davis et al., 1986).
We performed polymerase chain reaction–restriction frag-
ment length polymorphism (PCR-RFLP) with DNA amplifi-
cation by specific primers (forward primer: 5¢ - GGG TTT CCT
CAG AAC GAA CGT TGA - 3¢; reverse primer: 5¢ - TCA TTG
CTT TCC TTT TTC ACA A - 3¢), yielding a 460 base pair (bp)-
long fragment. This reaction was followed by digestion with
BsaXI enzyme (New England BioLabs Inc.), and samples were
analyzed by electrophoresis in 3% agarose gel. Genotypes
were confirmed in 24 samples with suboptimal PCR ampli-
fication by direct DNA sequencing on a MegaBACE 1000
DNA Analysis System (GE Healthcare).
In normal subjects, the restriction enzyme BsaXI acts on
specific binding sites by cutting the PCR product into three
fragments: 241, 189, and 30 base pairs long. Fragments
bearing the V617F mutation have their restriction site abol-
ished. Thus, samples with mixed cellularity due to a rela-
tively lower mutation burden present with four fragments
(460, 241, 189, and 30 bp), while samples with a high mutated
allele burden present with only 460 bp-long, digestion-
resistant fragments.
Results and Discussion
A total of 144 samples were collected: 52 PV (18 male, mean
age 69 – 11 years), 81 ET (23 male, mean age 63 – 18 years), and
11 PMF (5 male, mean age 63 – 10 years). One study had
suggested that sex could be a determining factor, as ET was
more common in women, while men were predominant in PV
(Campbell and Green, 2006). In the present study, women
were more frequently found in both PV (65.4%) and ET
(71.6%) groups.
Among the PV samples, JAK2 V617F was detected in 46
(88%). Thirty-nine of 81 (47%) ET patients bore the mutation,
while 8 (77%) of 11 PMF patients were JAK2 V617-positive.
Samples screened positive for JAK2 V617F were further clas-
sified according to the pattern of fragments obtained in the
PCR-RFLP reactions as ‘‘high burden’’ or ‘‘low burden.’’ These
data are summarized in Table 1.
Our data show that, when present in PV and ET patients,
the mutated JAK2 V617F allele burden was more frequently
low (63% and 74%, respectively). Higher mutation burden
rates were found in both diseases compared with previous
reports (25%–30% in PV and 2% in ET) (Baxter et al., 2005;
Kralovics et al., 2005; Levine et al., 2005), although still lower
than rates found in an Indian population (Sazawal et al., 2010).
In the latter study, the mutation was also determined by PCR-
RFLP, so a possible explanation for a higher mutation burden
in both India and Brazil could be that patients present later in
the course of the diseases in these developing countries, as
suggested by Sazawal and collaborators.
Table 2 compares the findings of this study with previously
published work and highlights that different methods are
available to detect JAK2 V617F, for example, allele-specific
PCR (AS-PCR), real-time PCR (RT-PCR), multiple direct
DNA sequencing methods, including mass spectrometry-
based platforms and, as has been the main approach of the
current study, PCR-RFLP. Sensitivity among the methods
Table 1. Mutated Allele Burden for JAK2 V617F
in Patients with BCR/ABL-Negative
Myeloproliferative Neoplasms Followed








PV 17 (32%) 29 (56%) 6 (12%) 52
ET 10 (12%) 29 (35%) 42 (53%) 81
PMF 7 (63%) 1 (14%) 3 (23%) 11
Data are represented as absolute number (percentage of patients in
each group).
PV, polycythemia vera; ET, essential thrombocythemia; PMF,
primary myelofibrosis.
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varies and has been well reviewed elsewhere (Steensma,
2006; Cankovic et al., 2009). Briefly, PCR-RFLP has been
demonstrated to be able to detect down to 20% of mutated
DNA on a wild-type background (Baxter et al., 2005; James
et al., 2005), and automated sequencing using autoradiogra-
phy as commonly used in the past was even less sensitive.
Current DNA sequencing methods may prove sensitive
down to 5%–10% of mutated DNA depending on the sample
type (cell lines or human) and purity, but RT-PCR techniques
have increased sensitivity to 2%–4%, and AS-PCR-based
studies have reported down to 0.01% of detectable JAK2
V617F-positive DNA (McClure et al., 2006). Nevertheless,
variation in mutation prevalence in the compared studies
considered appears to rely more on sample number disparity
than on differences among methods used, further confirming
the utility of PCR-RFLP as a simple and cost-effective method
to screen this mutation.
Despite a multicentric study having demonstrated that the
presence of JAK2 V617F in PMF does not determine any
specific clinical manifestation, such patients present with
poorer survival (Campbell et al., 2006). We found that 77% of
the PMF patients were JAK2 V617-positive. Even though our
small number of patients (n = 11) does not allow to draw any
definitive conclusion about the mutation prevalence in this
disease in our population, this finding still calls attention to
the need for target-specific therapies for this kind of MPN
with a worse outcome.
The prevalence of the JAK2 V617F mutation in MPNs in this
study was similar to what has been described by other groups
around the globe, and confirms that its high prevalence
among PV patients allows a more confident diagnosis of this
disease. Nonetheless, the diagnosis of all BCR-ABL-
negative MPNs, particularly JAK2 V617F-negative PV, should
rely on the criteria published in the 2008 WHO classification
(Tefferi et al., 2007). A negative screening for JAK2 V617F,
found in over a third (51/144) of the patients in this study,
should not be considered evidence enough to discard the di-
agnosis of a MPN. Still, screening for this mutation may help
physicians narrow down their diagnostic possibilities when a
BCR-ABL-negative MPN is suspected, as positivity for JAK2
V617F is virtually 100% specific for the distinction between
PV and other causes of increased hematocrit ( James et al.,
2006).
Previous studies in Brazil have been performed only in the
Southeastern part of the country, in the State of São Paulo
(Monte-Mór et al., 2007; Tognon et al., 2011). This is the first
study in the Brazilian Northeastern population, and while our
data did not differ from other Brazilian or worldwide popu-
lations, this suggests that the development of JAK2 V617F-
positive MPNs may occur rather independently from an
ethnical background. The availability of JAK2 V617F screen-
ing may help define better therapeutic strategies for patients
with MPNs in our region in the future, especially considering
current promising developments in clinical trials with JAK2
inhibitors (Verstovsek et al., 2010; Pardanani et al., 2011).
Moreover, this study highlights the need for collaboration in
further molecular studies on the pathogenesis of BCR-ABL-
negative JAK2 V617F-negative MPNs.
Table 2. Comparison of the Prevalence and Methods Used for Detection of JAK2 V617F
in BCR/ABL-Negative Myeloproliferative Neoplasms Among Different Studies
Study (number of patients







Silva et al. (present study) 88% (46) 47% (39) 77% (8)
(n = 144) PCR-RFLP n = 52 n = 81 n = 11
Mahfouz et al. (2011) 100% (13) 68% (28) NR
(n = 54) RT-PCR n = 13 n = 41 NR
Ayad and Nafea (2011) 81% (44) 57% (17) 46% (18)
(n = 123) AS-PCR n = 54 n = 30 n = 39
Tognon et al. (2011) 83% (10) NR NR
(n = 49) RT-PCR n = 12 n = 26 n = 11
Sazawal et al. (2010) 82% (28) 70% (7) 52% (16)
(n = 75) PCR-RFLP n = 34 n = 10 n = 31
Zhang et al. (2010) 82% (73) 36% (52) 51% (24)
(n = 278) AS-PCR, DNA seq, MS n = 89 n = 142 n = 47
Basquiera et al. (2009) 89% (40) 69% (30) 47% (7)
(n = 103) AS-PCR n = 45 n = 43 n = 15
Monte-Mór et al. (2007) 96% (47) 28% (8) 56% (14)
(n = 103) PCR-RFLP n = 49 n = 29 n = 25
Levine et al. (2005) 74% (121) 33% (37) 35% (16)
(n = 325) DNA seq, MS n = 164 n = 115 n = 46
Baxter et al. (2005) 97% (71) 57% (29) 50% (8)
(n = 140) AS-PCR, DNA seq n = 73 n = 51 n = 16
Kravolics et al. (2005) 65% (83) 23% (21) 57 (13)
(n = 244) DNA seq n = 128 n = 93 n = 23
James et al. (2005) 89% (40) 43% (9) 43% (3)
(n = 73) DNA seq n = 45 n = 21 n = 7
Data are represented as percentage of patients in each group (absolute number).
NR, not reported; PCR-RFLP, polymerase chain reaction–restriction fragment length polymorphism; RT-PCR, real-time polymerase chain
reaction; AS-PCR, allele-specific polymerase chain reaction; DNA seq, DNA sequencing; MS, mass spectrometry-based method.
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